^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Title:

    trametinib (Mekinist®) is accepted for restricted use within NHSScotland.

    Excerpt:
    trametinib (Mekinist) is accepted for restricted use within NHSScotland....in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

    Excerpt:
    ...- Known positive RAS (NRAS or KRAS or HRAS) or BRAFV600E or K601E mutation (determined on a previous analysis and/or on a representative formalin-fixed paraffin embedded (FFPE) tumor samples sent for central testing or on a biopsy sample sent for central testing)....
    Trial ID:
    MERAIODE
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Am J Med
    Title:

    Concurrent Anaplastic and Papillary Thyroid Carcinomas: A Case Report

    Published date:
    04/22/2020
    Excerpt:
    It is also possible that the relatively longer survival in our patient is due to the use of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib in this case with concurrent ATC and PTC.
    DOI:
    10.12691/ajmcr-8-7-11